Actively Recruiting
A Prospective Study on the Diagnosis of Malignant Tumors Using 18F-FGIn PET/CT Imaging
Led by Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Updated on 2026-05-22
110
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Glutamine, an important nutrient for cancer cell growth, is often disrupted in cancer metabolism. Researchers are studying 18F-FGln PET/CT imaging, a new method that targets this altered glutamine metabolism, to see how well it diagnoses different types of malignant tumors. This observational study aims to evaluate the diagnostic value of 18F-FGln PET/CT in patients with various cancers, using tissue diagnosis as the reference standard. Participants are patients suspected of or confirmed to have malignant tumors who undergo an 18F-FGln PET/CT scan. This imaging test tracks how cancer cells use glutamine, providing detailed pictures that may help in tumor detection and treatment planning. The study focuses on comparing this imaging method with current standards across a range of cancers, including brain, liver, gastric, duodenal, colorectal, and ovarian cancers. During the study, participants will have a PET/CT scan where measurements like SUVMAX and tumor-to-background ratio (TBR) will be recorded within one day after the scan. Researchers will monitor the imaging results to assess the tracer's ability to detect tumors accurately. The study involves patients aged 18 to 70 years, who follow the research protocol and provide consent. Participation includes compliance with imaging procedures and clinical evaluations related to cancer diagnosis and management.
CONDITIONS
Brief Title
A Prospective Study on the Diagnosis of Malignant Tumors With 18F-FGIn PET/CT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with clinical suspicion or confirmation of primary or recurrent malignant tumors such as glioma, liver cancer, gastric cancer, duodenal cancer, colorectal cancer, or ovarian cancer
- Patients undergoing tumor staging or treatment evaluation with 18F-FDG PET/CT or 18F-FGln PET/CT
- Patients without history of other tumors
- Patients who can comply with study procedures and provide informed consent
You will not qualify if you...
- Pregnant or lactating patients
- Patients under 18 years old
- Patients or legal representatives unable or unwilling to provide written informed consent
- Patients with poor compliance or unable to tolerate PET/CT scans
- Patients who had gastrointestinal barium meal examination within one week
- Any other condition deemed inappropriate by investigators for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessment
Duration - 1 day
Participants undergo an 18F-FGln PET/CT scan to evaluate malignant tumors based on glutamine metabolism.
1 visit (in-person) for PET/CT scan
Duration - Up to several weeks depending on clinical follow-up
Participants are observed after the PET/CT scan to monitor outcomes and confirm diagnosis with histopathology.
Follow-up visits as per routine clinical care
Trial Site Locations
Total: 1 location
1
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Guangzhou, China
Actively Recruiting
Research Team
R
Rusen Zhang
H
HAO PENG
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here